Antigene oligonucleotides have the potential to regulate gene expression through site-specific DNA binding. However, in vivo applications have been hindered by inefficient cellular uptake, degradation, and strand displacement. Peptide nucleic acids (PNAs) address several of these problems, as they are resistant to degradation and bind DNA with high affinity. We designed two cationic pyrimidine bis-PNAs (cpy-PNAs) to target the polypurine tract of the HER-2/neu promoter and compared them to an unmodified phosphodiester triplex-forming oligonucleotide (TFO1) and a TFO-nitrogen mustard conjugate (TFO2). PNA1 contains a ؉2 charge and bound two adjacent 9-bp target sequences with high affinity and specificity, but only at low pH. PNA2 contains a ؉5 charge and bound one 11-bp target with high affinity up to pH 7.4, but with lower specificity. The PNA:DNA:PNA triplex formed by these cpy-bis-PNAs presented a stable barrier to DNA polymerase extension. The cpy-bis-PNAs and the TFO-alkylator conjugate prevented HER-2/neu transcription in a reporter gene assay (TFO2 ‫؍‬ PNA1 Ͼ PNA2 ϾϾ TFO1). Both PNAs and TFOs were effective at binding the target sequence in naked genomic DNA, but only the TFO-alkylator (TFO2) and the more cationic PNA (PNA2) were detected at the endogenous HER-2/neu promoter in permeabilized cells. This work demonstrates the potential for preventing HER-2/neu gene expression with cpy-bis-PNAs in tumor cells.
INTRODUCTION O
LIGONUCLEOTIDES (OLIGOS) have the potential to target DNA site specifically and regulate gene expression, prevent DNA replication, and induce site-specific mutations (Guntaka et al., 2003) . These properties could ultimately lead to new treatments for a wide variety of genetic and infectious diseases, including cancer and HIV infection (Cho-Chung, 2002; Laskin and Sandler, 2004; Orr, 2001; Rudin et al., 2004) . Oligos that are designed to target DNA in order to interfere with gene expression are known as antigene oligos. Triplexforming oligos (TFOs) are antigene oligos that bind to polypurine-polypyrimidine DNA tracts and form base triplets by Hoogsteen bonding to double-stranded DNA (dsDNA). Triplex-forming oligonucleotides have been demonstrated to recognize and bind target sequences within the structured chromatin of permeabilized cells (Giovannangeli 1997) or isolated nuclei (Besch et al., 2002) . Further evidence of the ability of TFOs to bind to target sequences within living cells comes from the ability of TFOs to mediate mutagenesis at the target site in yeast cells (Barre et al., 2000) , cultured mammalian cells (Vasquez et al., 1999 (Vasquez et al., , 2001 Wang et al., 1996) , and mice (Vasquez et al., 2000) . TFO binding to the target sequence in intact mammalian cells was also demonstrated by site-specific, TFO-directed strand cleavage (Sedelnikova et al., 2002) . Although mutagenesis or cleavage events are infrequent, they have unambiguously demonstrated that a TFO can bind to a target sequence in living Arizona Cancer Center, Tucson, AZ 85724. cells. TFOs have also been shown to prevent transcription initiation or elongation from plasmid DNA transfected into cells (Faria et al., 2001; Kim et al., 1998; Ziemba et al., 2003) , but few studies have evaluated the regulation of endogenous gene expression by TFOs. One promising study demonstrated biologic activity in cells by a TFO and also indicated specific target interactions (Majumdar et al., 2003) . Other recent reports demonstrated antigene effects of TFOs at endogenous targets in cell culture (Besch et al., 2002; Carbone et al., 2003 Carbone et al., , 2004 but did not confirm site-specific binding in viable cells. To date, antigene activity by a TFO has not been demonstrated to be caused by direct interactions at the intended target sequence in living cells.
Peptide nucleic acids (PNAs) are DNA mimics in which the sugar-phosphate backbone of DNA is replaced by an uncharged aminoethylglycine backbone. PNAs were first reported in 1991 (Nielsen et al., 1991) and have since been shown to interact with single-stranded, double-stranded, hairpin, and quadruplex DNA, as well as RNA (Armitage, 2003) . PNAs have great potential as an antigene therapy for targeting of chromosomal DNA (Kaihatsu et al., 2004b) . Compared with DNA and many DNA analogs, PNAs have a higher affinity for complementary DNA and RNA sequences, bind less to proteins, and are less susceptible to degradation by nucleases or proteases (Demidov et al., 1994; Uhlmann, 1998) . The DNA:DNA:DNA triple helix is recognized by DNA repair proteins (Vasquez et al., 2002) and displaced by helicases (Maine and Kodadek, 1994) , but PNAs are less susceptible to unwinding by helicases (Bastide et al., 1999; Tackett et al., 2002) and block DNA polymerase elongation when bound to duplex DNA . Pyrimidine-rich PNAs can bind to a polypurine DNA sequence by strand invasion and form a PNA:DNA:PNA triple helix, differentiating PNAs from DNA-binding oligos described to date. In this complex, one PNA molecule binds the purine-rich DNA strand by Hoogsteen bonds while a second PNA molecule binds by Watson-Crick base pairing, displacing the noncomplementary pyrimidine DNA strand Nielsen, 2001; Nielsen et al., 1991) . A theoretical analysis indicated that the Hoogsteen base pairing occurs first, followed by strand invasion and Watson-Crick base pairing, resulting in formation of a P-loop (Kuhn et al., 1999) . Local distortion of the double helix appears to be the rate-limiting step for PNA invasion (Bentin and Nielsen, 1996; Demidov et al., 1995; Larsen and Nielsen, 1996) . The rate of PNA binding and strand invasion may be improved by linking the two single pyrimidine-rich PNA molecules by a flexible linker (bis-PNAs) and the inclusion of cationic lysine residues (cationic pyrimidine PNAs, cpy-PNAs) (Griffith et al., 1995) . Finally, the formation of a pyrimidine motif triple helix requires protonation of cytosines and is facilitated at neutral pH by J-TARGETING THE HER-2/NEU PROMOTER 37 base (pseudoisocytosine) substitutions (Egholm et al., 1995) . In cell-free models and in tissue culture, PNAs can both inhibit and activate transcription, prevent DNA replication, and induce mutations in chromosomal DNA (Diviacco et al., 2001; Faruqi et al., 1998; Larsen and Nielsen, 1996; Mollegaard et al., 1994; Nielsen et al., 1994; Wang et al., 1999 Wang et al., , 2001 Zhao et al., 2003) . One drawback is that PNAs are more difficult to deliver to cultured cells than DNA oligos because their neutrally charged backbone (Chinnery et al., 1999) is not amenable to PNA inclusion in most of the commonly used DNA transfection reagents. Recently, several groups have shown that PNAs conjugated to either lipophilic moieties or to cell-penetrating peptides (CPPs) can effectively deliver PNAs to cultured cells (Kaihatsu et al., 2004a; Koppelhus and Nielsen, 2003) . The HER-2/neu oncogene is overexpressed in numerous types of human cancer, and its overexpression often correlates with poor clinical outcome (Cirisano and Karlan, 1996; Jardines et al., 1993) . The apparent involvement of HER-2/neu in tumor progression and metastasis makes it an attractive target for cancer therapeutics. The HER-2/neu promoter contains a polypurine tract within a region of transcriptional importance, overlapping a transcription initiator sequence and just upstream of the TATAA box, both of which are capable of independently controlling transcription initiation (Mizuguchi et al., 1994) . TFOs targeting this polypurine tract can disrupt transcription factor binding and prevent transcription (Ebbinghaus et al., 1993; Noonberg et al., 1994; Porumb et al., 1996; Ziemba et al., 2003) . However, we have observed previously that a triple helix formed within this sequence does not persist in cells unless third strand binding is stabilized by covalent adducts with the target sequence using a TFO-alkylator conjugate (Ziemba et al., 2003) . In the present work, we designed bis-PNAs predicted to bind to the HER-2/neu promoter with sufficient stability to mediate antigene effects in cells without the need for covalent binding to the target sequence. We demonstrate that two different bis-PNA molecules can target the HER-2/neu promoter and inhibit HER-2 transcription comparable to a TFO-alkylator conjugate in a reporter plasmid. PNA binding was detected at the endogenous HER-2/neu promoter in permeabilized breast cancer cells with an amplified HER-2/neu gene.
MATERIALS AND METHODS

Oligonucleotide synthesis
PNAs were purchased from Applied Biosystems (Foster City, CA) (PNA1) and Biosynthesis, Inc. (Lewisville, TX) (PNA2) and the sequences are PNA1, NH2-TC-CTCCTCC-OOO-Lys-CCTCCTCCT; PNA2, NH2-LysLys-CCTCCTCCTCC-OOO-CCTCCTCCTC-Lys-Lys. The PNA arms were separated by three linker molecules (O, 2-amino-ethoxy-2-ethoxyacetic acid). Lysine (lys) residues were incorporated where indicated. The PNAs were aliquoted in siliconized tubes, stored at 4°C for less than 2 months, and preheated to 50°C for 10 minutes prior to use. DNA oligos were purchased from Qiagen Operon (Chatsworth, CA) and gel purified before use. TFO sequences are TFO1, 3Ј-AGGAGAAGGAGGAG-GCGGAGGAGGAGGG; TFO2, 3Ј-PAM-GAGAAG-GAGGAGGCGGAGGAGGAGG-PAM. TFO2 was synthesized with a C6-amino group at both the 5Ј-end and 3Ј-end, conjugated to phenylacetic acid mustard (PAM), and purified by reverse-phase high-performance liquid chromatography (HPLC) as previously described (Ziemba et al., 2003) . Guanine residues in TFO2 were substituted with 8-aza-7-deazaguanine (PPG) to prevent self-association of the TFO (Ebbinghaus et al., 1999; Lampe et al., 1997) .
Electrophoretic mobility shift assays (EMSAs)
Synthetic duplexes were formed with complementary oligos that were end-labeled on either the pyrimidine or the purine strand, annealed, and gel purified. The duplexes represented the native HER-2/neu promoter sequence from Ϫ214 to Ϫ249 (Fig. 1) , the HER-2/neu promoter sequence with 1-bp mismatches in the PNA binding sites (at Ϫ223 and Ϫ234), or a purine-rich control containing a PNA binding site with a 3-bp mismatch. In addition, an asymmetric HER-2/neu duplex (51-mer pyrimidine strand and 65-mer purine strand) was end-labeled on both strands to simultaneously demonstrate PNA binding to the purine strand and dissociation of the pyrimidine strand. Labeled duplexes (0.01 M) were incubated with increasing concentrations of PNA (0.1 nM-1 M). PNA binding reactions were performed in 10 mM NaPO 4 buffer, pH 6.5-7.4, at 37°C for 4 hours. The complexes were separated on a 12% native polyacrylamide gel and visualized by autoradiography. Because bis-PNA-induced invasion complexes form with high stability, the dissociation rate is low and often unmeasurable (Bentin et al., 2003) . Therefore, true thermodynamic equilibrium constants are not practical. In these experiments, the PNA binding affinity is described by the PNA concentration leading to conversion of 50% of the double-stranded target to single-stranded pyrimidine strand plus PNA:DNA complexes (C 50 ).
DNase I and S1 digestions
For DNase I footprinting on the purine strand, a 250-bp PstI/XmaI fragment of the HER-2/neu promoter was excised from pGL3/HNP410. The pGL3/HNP410 construct contains the HER-2/neu promoter from Ϫ410 to ϩ1 relative to the translation start site driving luciferase expres-sion (pGL3 basic) (Promega, Madison, WI). The restriction fragment was end-labeled on the top strand downstream of the target sequence by Klenow fill-in, and 0.1 M labeled probe was incubated with 0.01-1.0 M PNA, representing a 0.1-10ϫ molar ratio of PNA, at pH 6.5, or with 1 M (10ϫ molar ratio) of TFO1 in 1ϫTBM (90 mM Tris, pH 7.4, 90 mM borate, 10 mM MgCl 2 ). The reactions (0.01 M final) were incubated with 2 G dIdC in balance buffer (75 mM KCl, 20 mM Tris, pH 7.4) for 2 minutes at ambient temperature. An equal volume (10 l) of DNase dilution buffer (10 mM MgCl 2 , 10 mM CaCl 2 ) containing 0.1 U DNase I (Invitrogen, San Diego, CA) was added for 30 seconds at ambient temperature. Reactions were immediately terminated in formamide containing 20 mM EDTA and separated on a denaturing 8% sequencing gel. A Maxam and Gilbert G-reaction was performed to identify the protected guanine residues (Sambrook et al., 2001) . Competition experiments were performed by incubating 0.1 M PNA2 (1ϫ) with the labeled HER-2/neu promoter restriction fragment and either wild-type or purine-rich control duplexes as cold competitors. The cold competitor duplexes were added at 10-fold molar excess to the radiolabeled HER-2/neu promoter, either just before incubation with PNA2 or for 4 hours after the PNA was already bound to the radiolabeled HER-2/neu promoter.
For S1 probing of the pyrimidine strand, a 280-bp EcoRI/SmaI fragment of the pGL3/HNP410 plasmid was end-labeled on the bottom strand upstream of the target sequence by Klenow fill-in. The fragment was incubated with the indicated concentration of PNA1 or TFO1 at 37°C for 4 hours or overnight. The reaction was incubated with 10 U S1 endonuclease in 0.5ϫ S1 endonuclease buffer (Fisher Scientific, Pittsburgh, PA) at ambient temperature for 20 minutes. The reaction conditions were optimized so that 50% of the full-length fragment was cleaved by S1 endonuclease. Reactions were terminated in formamide containing 50 mM EDTA and separated on a denaturing 8% sequencing gel. A Maxam and Gilbert C-reaction was performed to identify the location of the S1 sensitive sites (Sambrook et al., 2001) .
DNA polymerase arrest assay
DNA polymerase arrest assays are a variation of a described technique (Han et al., 1999; Weitzmann et al., 1996) . The 86-mer template strand for primer extension contains the polypurine tract of the HER-2/neu promoter from Ϫ249 to Ϫ212 flanked by a primer binding (TCCAACTATGTATAC) and tail sequence (AGCG-GCACGCAATTGCTATAGTGAGTCGTATTA) (Fig.  4A ). End-labeled primer (0.67 M) and template strand (0.33 M) were annealed in a 30-l final volume. This primer-template heteroduplex was used for PNA binding and primer extension. For TFO binding, end-labeled primer and a 36-mer complement (0.67 M) to the polypurine tract of the HER-2/neu promoter were both annealed to the 86-mer template. Annealed heteroduplexes were gel purified to remove excess primer or pyrimidine complement.
PNAs were mixed with 0.01 M template-primer mixture in a 10-l final volume (NaPO 4 , pH 6.5 or 7.4) and incubated for 4 hours at 37°C before adding 1 mM MgCl 2 for DNA polymerase extension. TFOs were mixed with 0.01 M promoter primer-template mixture in a final volume of 10 l 1ϫTBM and incubated for 4 hours at 37°C. DNA polymerase extension was performed by adding 0.15 mM dNTPs and 5 U Taq DNA polymerase (Fermentas, Hanover, MD) for 20 minutes at 37°C. Taq was selected for these assays so that future studies could be performed to evaluate PNA stability at higher temperatures, but only 37°C was used here. The reactions were stopped by adding formamide loading buffer with 10 mM EDTA and 10 mM NaOH, and the extension products were resolved on a denaturing 8% sequencing gel. To identify the sites of polymerase arrest, a chain termination sequencing reaction was performed with the same primer-template mixture using ThermoSequenase (USB, Cleveland, OH) according to the manufacturer's instructions.
Transient transfections
HeLa cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and cultured as recommended. Site-directed mutagenesis was performed (Quickchange, Stratagene, La Jolla, CA) to generate mutant promoter plasmids using the normal plasmid pGL3/HNP410, and 6-bp mutations were introduced by engineering an SphI restriction site at target 1 from Ϫ237 to Ϫ232 (Ϫ237 plasmid) or at target 2 from Ϫ225 to Ϫ220 (Ϫ225 plasmid). Oligos (1-10 M) were incubated with plasmids (2 g) at 37°C for 4 hours in either 10 mM NaPO 4 buffer at pH 6.5 (for PNAs) or 1ϫTBM at pH 7.4 (for TFOs) and then mixed with lipofectamine (Invitrogen) and the internal control pRLSV40 renilla luciferase vector (Promega) for transfection into HeLa cells. Dual luciferase Assays (Promega) were performed at 24-72 hours, HER-2/neu-driven luciferase activity was normalized for transfection efficiency, and the data are presented relative to luciferase activity from untreated pGL3/HNP410 as previously described (Ziemba et al., 2003) .
Southern blot protection assay
Genomic DNA (gDNA) from SK-BR-3 cells (15 g) was heated to 50°C for 20 minutes and was incubated with PNAs in 10 mM NaPO 4 buffer (pH 6.5 or 7.4) for up to 24 hours. The TFO reaction was performed in 1ϫTBM without prior heating of gDNA. The gDNA was then digested with 1 U BbvI/g DNA for 2 hours at 37°C, separated on an agarose gel, and transferred to a nylon membrane. High stringency Southern hybridization was performed using a 300-bp internally radiolabeled PstI/ApaI fragment of the HER-2/neu promoter (Sambrook et al., 2001 ).
Digitonin permeabilization
Digitonin permeabilization was a slight modification of previously published methods (Duverger et al., 1995; Giovannangeli et al., 1997) . Briefly, SK-BR-3 cells were trypsinized and washed in phosphate-buffered saline (PBS) prior to treatment. Two million cells were incubated with 40 g/ml digitonin (Sigma, St. Louis, MO) in permeabilization buffer (Giovannangeli et al., 1997) at ambient temperature for 5 minutes, washed in digitoninfree buffer, and tested for permeabilization efficiency by trypan blue staining. Permeabilized cells were then incubated with 1 M TFO2 in triplex-forming buffer (10 mM Tris, pH 7.4, 50 mM NaCl, 10 mM MgCl 2 ) or with 10 M PNA in NaPO 4 buffer (10 mM NaPO 4 , pH 6.5-7.0, 50 mM NaCl) at 37°C for 4 hours with gentle rocking. Prior to genomic DNA isolation, cells were washed three times with 1ϫ PBS, and gDNA was isolated, digested with BbvI, and subjected to Southern hybridization as described.
RESULTS
PNA design and target sequences
The target sequence for PNA binding (Fig. 1) is a polypurine-polypyrimidine tract in the HER-2/neu promoter (Ϫ218-Ϫ245 relative to the translation start site) that overlaps an initiator-like sequence and lies between the TATA and CCAAT boxes (Mizuguchi et al., 1994) . In our recent work targeting this polypurine tract with TFOs, we demonstrated that an unmodified TFO (TFO1) rapidly dissociated from the target sequence in a plasmid that was transfected into tumor cells. To prevent HER-2/neu transcription, it was necessary to modify the TFO at both ends with a DNA alkylating agent, and triplex formation with this TFO-alkylator conjugate (TFO2) prevented recombinant helicase activity and persisted in cells for up to 72 hours (Ziemba et al., 2003) . For this reason, we designed cpy-bis-PNAs (PNA1, PNA2) to determine if the strand invasion complex was sufficiently stable to alleviate the need for covalent modification of the target sequence.
PNA1 contains two linked 9-mer with the sequence (TCC) 3 -(CCT) 3 designed to target (AGG) 3 sequences by the formation of a PNA:DNA:PNA triple helix. The target sequence contains two adjacent runs of AGG repeats (target 1 and target 2), so that two PNAs could bind simultaneously to the target sequence. PNA2 contains linked 10-mer and 11-mer arms designed to bind to target 2 in order to increase binding specificity (Fig. 1B) . Appending multiple lysine residues to cpy-bis-PNAs accelerates invasion complex formation (Egholm et al., 1995; Griffith et al., 1995) , and we compared binding affinity and specificity of PNA1 with a single lysine residue in the linker to PNA2 with four lysine residues, two on each terminus. PNA binding and the level of HER-2/neu promoter suppression in plasmid DNA in cells was compared with purine motif TFOs that were either unmodified (TFO1) or modified to contain 8-aza-7-deazaguanine substitutions and C6-PAM at the 5Ј and 3Ј termini (TFO2). Mismatched target sequences were designed to contain either a 1-bp alteration in the center of each target or a polypurine tract from an unrelated sequence containing a 3-bp mismatch (Fig. 1C) .
PNA binding affinity and specificity
Pyrimidine-rich PNAs invade duplex DNA in a pH-dependent manner (Demidov et al., 1995; Griffith et al., 1995) . Therefore, EMSAs were performed at different pHs using an end-labeled duplex target (Fig. 2) . Figure  2A illustrates the duplex target end-labeled on the pyrimidine strand and incubated with PNAs at pH 6.5, and the duplex is end-labeled on the purine-rich strand and incubated with PNAs at pH 7.4 in Figure 2B . For comparison of relative binding by PNAs under different conditions, the C 50 , defined as the concentration of PNA that produces 50% strand invasion under a given set of experimental conditions, is presented ( Fig. 2D) (Bentin et al., 2003) . PNA1 demonstrated pH-dependent strand invasion, with a high affinity for the target duplex at slightly acid or neutral pH (C 50 Ϸ 5 nM at pH 6.5 and 30 nM at pH 7.0) and a sharp decrease in binding at slightly alkaline pH (C 50 Ͼ 1 M at pH 7.4). In contrast, PNA2 demonstrated a high affinity for the target sequence over this pH range (C 50 Ϸ 2 nM at pH 6.5 and 40 nM at pH 7.4). Higher PNA concentrations caused the formation of several low mobility complexes with the purine strand. Multiple low mobility complexes are formed and explained by bis-PNA orientation, number of interacting molecules, direction of linker wrapping, and degree of dissociation of the labeled duplexes (Hansen et al., 2001) . PNA binding was rapid, and strand invasion with the short 36-mer duplex at pH 6.5 appeared to be complete at 1 hour (data not shown).
Binding studies with the single mismatched target duplex demonstrate that PNA1 has approximately 1000-fold higher specificity for the native duplex target than for the single mismatch. In contrast, PNA2 was less specific, with only 5-10-fold higher affinity for the native duplex than for the single base pair mismatch. Binding studies with an unrelated polypurine-polypyrimidine sequence containing three mismatches demonstrated no binding by PNA1 at any pH. In contrast, PNA2 bound this unrelated sequence with moderate affinity at low pH (C 50 Ϸ 0.1 M at pH 6.5) but not at pH 7.4 (C 50 Ͼ 1 The TATAA (Ϫ201 to Ϫ205) and CCAAT (Ϫ249 to Ϫ253) boxes are shown relative to the translation start site (double arrow). The major transcription start site (single arrow) is located at Ϫ120. (B) Schematic of PNA2 invasion complex with the HER-2/neu promoter. PNA2 was designed to target an 11-bp stretch of target 2. (C) Single base pair mutations (transition G to A) were incorporated in the center of each PNA target sequence to generate a 1-bp mismatch duplex. The target was assured to contain no introduced PNA target sites. A random purine-rich duplex was also generated containing a 3-bp mismatch.
A B C M).
Together, these data demonstrate that increasing the length and number of positive charges in a cpy-bis-PNA increases the binding affinity and at least partially overcomes the need for low pH for pyrimidine-rich PNAs to bind DNA. The improved binding, however, is at the cost of a fairly dramatic loss of target specificity. EMSAs were also performed with a longer, asymmetric duplex containing a 5Ј overhang on the purine strand and with both strands labeled to demonstrate that these PNAs bind to the purine strand and displace the pyrimidine strand (Fig. 2C ) in a concentration-dependent manner.
DNase I footprinting was performed to determine the precise PNA binding sites for PNA1 and PNA2 (Fig.  3A) . A 280-bp promoter fragment was end-labeled on the purine-rich strand and incubated with PNA or TFO. Complete protection of both target 1 and target 2 was detected within 30 minutes using a 10-fold molar excess of PNA1, and no nonspecific interactions were detected up to 24 hours. The HER-2/neu promoter target sequence was also incubated with a concentration gradient resulting in a 0.1-10ϫ molar ratio of both PNAs (0.01-1 M). Complete protection of both targets was detected at a 1:1 molar ratio for both PNA1 and PNA2, further demosntrating that PNA2 can bind with relatively high affinity to the single mismatch target sequence. The DNase I protection included both PNA targets, the 3 intervening bases, and partial protection of 4-6 bases on each side of the targets (FIg. 3D) . The PNA2 footprint appears to extend a few nucleotides farther upstream of target 1, likely due to interaction with another naturally occurring 1-bp mismatch target between Ϫ244 and Ϫ234. Competition experiments were performed with PNA2 to determine if an excess of specific targets or nonspecific DNA interferes with PNA binding (FIg. 3B) . Once bound to the HER-2/neu promoter, neither an excess of the specific competitor (the native duplex target, WT) nor an excess of the nonspecific competitor (purine-rich control, MM) could displace PNA2 from its binding sites. In contrast, a 10-fold excess of specific competitor prevented PNA2 from binding to the HER-2/neu promoter when added immediately prior to incubation with the radiolabeled HER-2/neu promoter fragment, whereas a 10-fold excess of the nonspecific competitor did not prevent binding to the labeled promoter fragment. These data suggest that PNA2 binding to the specific target sequence in the HER-2/neu promoter occurs more rapidly than binding to the nonspecific competitor DNA. S1 endonuclease was used to demonstrate strand displacement after PNA binding by digesting the exposed ssDNA loop (Demidov et al., 1993) . PNA1 caused sitespecific pyrimidine strand cleavage of the HER-2/neu promoter in both PNA target sites (Fig. 3C) . The region of cleavage extended a few base pairs upstream of the target sequences at high PNA concentrations (Fig. 3C) , but no other sites in the 280-bp promoter fragment were sensitive to S1 cleavage. No significant difference in the cleavage pattern was identified between 4-hour and overnight reaction times at any PNA concentration, further indicating a rapid rate of invasion complex formation. TFO1 did not displace the pyrimidine strand, as expected. Taken together, these data show the site specificity of strand invasion for the target sequence and dem- 
Inhibition of DNA polymerase extension
The ability of the bis-PNAs to inhibit the extension of a DNA polymerase was evaluated using a Taq polymerase arrest assay. Figure 4B demonstrates concentration-dependent arrest of labeled primer extension by Taq DNA polymerase due to the binding of both PNAs to a single-stranded template and formation of a PNA:DNA:PNA triple helix. At 0.01 M PNA, the template is in excess, and polymerase extension was partially blocked at both PNA binding sites. PNA1 and PNA2 demonstrated similar arrest patterns at pH 6.5 (FIg. 4B) , whereas at pH 7.4 (Fig. 4C) , only PNA2 blocked polymerase extension. PNA1 appears to have multiple polymerase stop sites at the downstream site due to the presence of two overlapping binding sequences within target 2. PNA2 has only a single target sequence within the same region. When the PNA is in molar excess (1 M) relative to the template, only the first arrest site is observed, with no full-length primer extension product. These results demonstrate that the PNA:DNA:PNA triple helix is very resistant to displacement by DNA polymerase and that PNA2 can form this structure at physiologic pH, whereas PNA1 cannot. We estimate the oligo concentration leading to 50% polymerase arrest (EC 50 ) relative to full-length primer extension product for both PNAs is approximately 5 nM at pH 6.5 and Ͼ1 M for PNA1 and Ϸ100 nM for PNA2 at pH 7.4. Figure 4D depicts the ability of an unmodified or bisalkylating TFO to arrest Taq polymerase elongation. For these experiments, a double-stranded template was required for triple helix formation, and a 36-mer pyrimidine-rich complement was annealed to the template to form a double-stranded region of the template for TFO binding. The complementary strand did not present a barrier to Taq polymerase elongation (untreated control lanes, 0 , Fig. 4C ). The triple helix formed by TFO1 partially blocked polymerase elongation at the highest con- A B C D centration tested (1 M), representing a 100-fold molar excess of the TFO. The EC 50 for TFO1 was approximately 500 nM. The triple helix and covalent guanine adducts formed by TFO2 present a more effective barrier to polymerase elongation than TFO1, with an EC 50 for TFO2 for approximately 50 nM. Collectively, these data demonstrate that an effectively bound bis-PNA presents a more stable barrier to displacement by an elongating DNA polymerase than a bis-alkylating TFO by an order of magnitude (EC 50 of 5 nM for PNA1 and PNA2 compared with 50 nM for TFO2).
Inhibition of intracellular HER-2/neu transcription from reporter plasmid
Inhibition of HER-2/neu expression was analyzed by transient transfection analysis with plasmid DNA that was incubated with PNAs or TFOs prior to transfection into HeLa cells, an easily transfected cervical cancer cell line (Fig. 5) . TFO2 was previously found to significantly suppress HER-2/neu promoter activity from a reporter plasmid in cells compared with TFO1 (Ziemba et al., 2003) . A 10-M concentration of the PNAs was used to rapidly saturate the PNA binding sites in the HER-2/neu promoter and demonstrate that PNA1 suppressed promoter activity by approximately 55%, whereas PNA2 suppressed HER-2/neu expression by approximately 40% at 24 hours (Fig. 5A) . TFO2 (at 1 M) suppressed HER-2/neu expression by approximately 60%, whereas TFO1 had no effect. Target specificity was demonstrated by showing that expression from an SV40-driven luciferase plasmid was not affected by treatment with PNAs (data not shown). These data indicate that the PNA:DNA:PNA invasion complex remains formed after transfection in tumor cells and presents a barrier to the formation of the transcription initiation complex. In contrast, the DNA:DNA:DNA triple helix requires covalent adduct formation with TFO2 to prevent HER-2/neu expression in (Ziemba et al., 2003) . To evaluate the specificity of PNA binding and the relative importance of the two potential PNA binding sites, PNA invasion complexes were formed in HER-2/neu luciferase constructs with mutations in either target 1, the upstream binding site (Ϫ237 to Ϫ232, designated Ϫ237 HER-2), or in target 2, the downstream binding site (Ϫ225 to Ϫ220, designated Ϫ225 HER-2). PNA1 and PNA2 both suppressed HER-2/neu expression by approximately 40% when bound only to target 2 in the Ϫ237 HER-2 construct. PNA1 binding only to target 1 had a small effect on HER-2/neu expression from the Ϫ225 HER-2 construct (Ϸ10%), whereas PNA2 had a greater effect on HER-2/neu transcription (Ϸ30%), even though its intended binding site was disrupted in this construct. These data suggest that PNA2 can bind to target 1 with a single mismatch, consistent with the relatively high affinity of PNA2 for a single mismatch target sequence (Fig. 2) . These data also show that targeting the downstream portion of the polypurine tract is more robust than targeting the upstream region and suggest that target 2 is more important to HER-2/neu transcription. It is interesting to note that a well-characterized ets binding site (EBS) is 7 bp downstream from target 2 (Scott et al., 2000) , and previous studies of TFOs targeting the polypurine tract demonstrated that a TFO could prevent PU.1 binding to the adjacent EBS in competition binding studies (Noonberg et al., 1994) . The stability of PNA and TFO-alkylator binding in cells was evaluated by time course analysis of HER-2/neu luciferase activity (Fig. 5B) . For this analysis, the plasmid was incubated with 1 M PNA or TFO, representing a 15-fold molar excess of oligo/plasmid. PNA2 at this concentration suppressed HER-2/neu transcription by only 30%-35%, but this level of suppression was retained up to 72 hours. PNA1 and TFO2 suppressed HER-2/neu expression by 55%-60%, but the magnitude of suppression of HER-2/neu expression by both PNA1 and TFO2 decreased over time to a similar degree, so that at 72 hours, HER-2/neu expression was only reduced by 20%-30%, favoring TFO2. To test for the possibility of plasmid degradation as a result of the presence of the PNA clamp, we performed restriction digestion and Southern analysis on PNA1-treated vs. untreated plasmid extracted from cells at 24-72 hours after transfection. We did not observe degradation of the plasmid due to the presence of the PNA (data not shown), nor have we previously observed degradation of a transiently transfected plasmid due to the presence of a TFO-alkylator (Faria et al., 2001; Kim, et al., 1998; Ziemba et al., 2003) . Collectively, these data demonstrate that a PNA:DNA:PNA complex can remain stably associated in cells and prevent transcription initiation from a reporter plasmid. An increase in the number of positive charges in a cpy-bis-PNA appears to decrease the specificity of PNA binding but increase the stability of the invasion complex in this model system to a degree that is comparable if not superior to a TFO bound with dual covalent adducts.
PNA binding to HER-2/neu promoter in gDNA
Oligonucleotide binding to the HER-2/neu target can be detected by preventing restriction endonuclease cleavage of an ideally located BbvI site within the PNA target sequence (Fig. 6) . Digestion of the HER-2/neu promoter with BbvI results in two fragments of 108 bp and 178 bp, whereas TFO or PNA binding prevents cleavage at the internal BbvI site, resulting in a single 286-bp fragment (Fig. 6A) . can be used to determine the amount of oligo binding semiquantitatively. Southern blot protection assays were performed to directly demonstrate PNA binding to the HER-2/neu promoter in naked gDNA and in tumor cells permeabilized with digitonin (Fig. 6B,C) . gDNA was heated to 50°C for 20 minutes to promote duplex opening prior to incubation with PNAs at 37°C. gDNA was incubated with PNAs for 4 hours at pH 7.4, and efficient binding to the HER-2/neu promoter was observed with PNA2 at a high concentration (10 M) but was not observed with PNA1 at any concentration. With prolonged incubation and lower pH, PNA binding to the HER-2/neu promoter in gDNA was demonstrated at 1 M for both PNA1 and PNA2. Under these conditions, the HER-2/neu promoter is completely bound by PNA2 at 24 hours and approximately 50% bound by PNA1 at 24 hours. To determine if TFO or PNA binding was detectable in the endogenous HER-2/neu promoter in tumor cells, we performed this assay in digitonin-permeabilized SK-BR-3 cells in which the HER-2/neu gene is amplified approximately 8-fold (Fig. 6C) . Permeabilized cells were incubated with TFO2 (1 M) for 4 hours in a buffer containing 10 mM MgCl 2 , and binding to the HER-2/neu promoter was observed at a level of approximately 50%. Permeabilized SK-BR-3 cells were suspended with 10 M PNA1 or PNA2 in a buffer adjusted to pH 6.5 or 7.0 for 4 hours. Binding to the endogenous HER-2/neu promoter by PNA2, but not PNA1, was detectable (approxi- 
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mately 5% at pH 6.5, trace at pH 7.0) in permeabilized cells.
In summary, these studies demonstrate site-specific targeting of the HER-2/neu promoter with cpy-bis-PNAs. PNA1 can bind to two adjacent polypurine repeat sequences in the HER-2/neu promotor with high affinity and specificity, leading to significant suppression of HER-2/new transcription, but this PNA lacks a sufficient number of positive charges to bind to gDNA efficiently and binds only at a low pH. PNA2 can also target the HER-2/neu promoter with high affinity and because of a greater number of lysines, can bind efficiently to gDNA as well as short synthetic sequences at physiologic pH, but at the expense of a loss of specificity. The improvement in binding affinity allows for PNA2 to bind to its intended target sequence in the HER-2/neu promoter in permeabilized cells.
DISCUSSION
In spite of obstacles to the development of effective therapeutic nucleic acid drugs, the ability to control specific gene expression using antigene oligos remains of substantial interest. In fact, a great deal of current research focuses on understanding the molecular mechanisms of nucleic acid interactions and developing new high-affinity oligonucleotides and oligonucleotide mimics (Demidov and FrankKamenetskii, 2004) . The current study directly compares two antigene oligo strategies, a DNA-based TFO conjugated to covalent DNA-modifying agents and bis-PNAs designed to form a stable strand invasion triple helix without conjugation to additional agents, all targeting the same polypurine tract in the HER-2/neu promoter. These data demonstrate the ability of bis-PNAs to strand invade at this polypurine tract and prevent HER-2/neu transcription in tumor cells when the strand invasion complex is preformed in a reporter plasmid. Interestingly, these data demonstrate the relative importance of targeting the distal portion of the polypurine tract, suggesting that strand invasion and alteration of the double helix at this location may be more likely to disrupt transcription factor binding to an adjacent EBS. PNA1, designed to bind to two adjacent polypurine repeats, is able to prevent HER-2/neu transcription from plasmid DNA to a degree similar to that of a TFO-alkylator conjugate, whereas PNA2, designed to bind to only one of these sites, is slightly less effective. The resistance of the PNA:DNA:PNA triple helix to displacement by DNA helicases has been described previously (Bastide et al., 1999; Tackett et al., 2002) . Our studies expand on these observations and demonstrate that the PNA:DNA:PNA triple helix is more stable to displacement by an elongating DNA polymerase than a DNA:DNA:DNA triple helix with guanine adducts at both ends. The persistence of promoter sup-pression provides an indirect measurement of the stability of the invasion complex within cells and demonstrate that the PNA invasion complex is at least as stable in cells as a TFO stabilized by the formation of dual guanine adducts and may be moreso with more cationic PNAs.
The pyrimidine bis-PNAs used in these studies have the drawback of pH dependence in the formation of the invasion complex because of the need for cytosine protonation for the Hoogsteen bonds involved in forming the invasion triple helix, a problem that may be overcome by incorporating a modified cytosine base, such as the Jbase, in place of cytosine (Demidov and Frank-Kamen etskii, 2001) . Only recently has the synthesis of PNA molecules containing the J-base substitution become commercially available. In the present studies, the addition of three more positive charges dramatically increased target binding at neutral pH, but at the expense of lower target specificity. The optimal number of lysines for a given sequence will balance high affinity against specificity. Increasing the number of positive charges in a cpy-bis-PNA molecule also accelerates strand invasion by improving the electrostatic interaction of the otherwise neutrally charged PNA with the phosphodiester backbone of DNA (Griffith et al., 1995; Kuhn et al., 1998) . This concept was demonstrated in our studies where a PNA with four lysines bound to its genomic target more effectively than a PNA with one lysine even at low pH. The binding of both PNAs to the HER-2/neu target sequence in gDNA was slower than the binding of TFO, likely due to the presence of an increase in potential binding sites for this PNA, a large increase in nontarget DNA, and the need for strand opening (Abibi et al., 2004) . Some groups are currently designing PNA modifications that should improve binding to duplex DNA targets of both homopurine and mixed sequence motifs (Pokorski et al., 2004; .
In vivo applications of antigene oligos of any composition remain hindered by inefficient uptake in cells. In spite of demonstrating the uptake of fluorescently labeled PNA conjugated to the well-characterized Antennapedia cell-penetrating peptide, we have been unable to demonstrate any antigene effects on endogenous HER-2/neu expression thus far. In these studies, we have directly demonstrated that a cpy-bis-PNA is capable of binding to the HER-2/neu promoter in permeabilized tumor cells, suggesting that with effective delivery and optimal PNA design, antigene effects might be observed. In our studies, a TFO bound to the endogenous target sequence much more efficiently, suggesting that this region of DNA is probably accessible to antigene oligo binding. A cautionary note has been raised in the interpretation of data demonstrating intracellular binding by a TFO when ligation-mediated PCR (LM-PCR) is used (Becker and Maher, 1999) . Contamination of the DNA preparations with the TFO was found to inhibit ligation of the unidirectional linker in an apparently site-specific manner. Oligonucleotide adherence to the cell surface is a well-recognized source of artifact with fluorescently labeled oligonucleotides and can be minimized by careful washing. In our studies, we washed cell pellets twice prior to DNA extractions. In experiments in which TFO2 was added to the permeabilized cells in a mock treatment just prior to pelleting and washing, we observed no evidence of TFO binding (data not shown). We believe that this assay is a powerful tool for detecting site-specific binding by TFOs and PNAs in cells, and this method is readily applicable to correlate reports of antigene activity with DNA binding by the oligonucleotide.
It is possible that the nuclear membrane is an additional barrier to PNA uptake. Whereas DNA oligos and analogs microinjected into the cytoplasm rapidly distribute to the nucleus (Leonetti et al., 1991) and, in fact, undergo active transport into the nucleus through nuclear pores (Lorenz et al., 2000) , the subcellular trafficking of PNA oligomers is poorly characterized, and nuclear uptake may be less efficient (Gray et al., 1997) . Some studies have demonstrated that a nuclear localization signal improves the uptake and antisense or antigene activity of PNAs (Cutrona et al., 2000; Gait, 2003; Rapozzi et al., 2002) . Nuclear localization signals are generally composed of cationic amino acids, and these molecules may also promote strand invasion. More likely, PNA binding is rate limited by transient opening of the duplex for effective strand invasion, whereas TFO binding is not. Prior studies have demonstrated that bis-PNA binding can be accelerated more than 10-fold by a DNA-binding agent that probably does so by inducing distortions of the double helix to promote PNA invasion (Mollegaard et al., 2000) .
In summary, these data demonstrate that bis-PNAs have some advantages over TFOs as antigen oligos in the formation of stable invasion complexes but have some drawbacks in the efficiency and specificity of complex formation under physiologic conditions. In order to overcome these drawbacks, the length and charge of a cpybis-PNA must be optimized to balance specificity against efficient DNA binding. We infer from the marked effect of pH on strand invasion by PNA1, a cpy-bis-PNA with only a single lysine, that Hoogsteen binding precedes and, in fact, drives strand invasion. Thus, modification of the Hoogsteen strand of the bis-PNA with the J-base improves triplex formation and may speed the formation of the strand invasion complex. However, once formed, even without the J-base, the invasion complex is highly stable even under conditions not favorable to the initial formation of the complex (as shown by the persistence of inhibition of HER-2/neu transcription by the bis-PNA in cells). We postulate that further improvements in triplex formation, for example, by conjugation of the Hoogsteen strand of the bis-PNA to a covalent DNA-modifying agent, such as a DNA alkylator, will improve the efficiency of strand invasion. We believe that the current data provide a foundation for such improvements and demonstrate the potential of an optimally designed bis-PNA to suppress HER-2/neu overexpression.
